Naglazyme Approval History
- FDA approved: Yes (First approved May 31st, 2005)
- Brand name: Naglazyme
- Generic name: galsulfase
- Previous name: Aryplase
- Company: BioMarin Pharmaceutical Inc.
- Treatment for: Mucopolysaccharidosis Type VI
Naglazyme (galsulfase) is an enzyme-replacement therapy for treatment of mucopolysaccharidosis VI (MPS VI), an inherited, life-threatening lysosomal storage disorder caused by a deficiency of the lysosomal enzyme N-acetylgalactosamine 4-sulfatase (also known as arylsulfatase B).
Development History and FDA Approval Process for Naglazyme
|May 31, 2005||Naglazyme BioMarin Pharmaceutical Inc. - Treatment for Mucopolysaccharidosis VI (MPS VI)|
|Nov 29, 2004||BioMarin Submits U.S. Biologics License Application for Marketing Authorization of Aryplase for MPS VI|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.